NANOBIOTECHNOLOGY LAB
RNAi - Drug Delivery - Biomaterials - Nanotechnology
2025
21 / Yadav N, Boulos J, Alexander-Bryant A, Cook K. Stochastic model of siRNA endosomal escape mediated by fusogenic peptides. Math Biosci. 2025 Jun 5;387:109476. doi: 10.1016/j.mbs.2025.109476. Epub ahead of print. PMID: 40482915.
20 / Alatise KL, Samec T, Coffin C, Gilmore S, Hazelton A, Xia R, Jones C, Alexander-Bryant A. Multifunctional Tandem Peptide Mediates Targeted siRNA Delivery to Ovarian Cancer Cells. ACS Appl Bio Mater. 2025 Jun 16;8(6):4612-4620. doi: 10.1021/acsabm.4c01545. Epub 2025 Jun 4. PMID: 40465375.
19 / Eckert T, Zobaer MS, Boulos J, Alexander-Bryant A, Baker TG, Rivers C, Das A, Vandergrift WA, Martinez J, Zukas A, Lindhorst SM, Patel S, Strickland B, Rowland NC. Immune Resistance in Glioblastoma: Understanding the Barriers to ICI and CAR-T Cell Therapy. Cancers (Basel). 2025 Jan 29;17(3):462. doi: 10.3390/cancers17030462. PMID: 39941829; PMCID: PMC11816167
2024
18 / Attia MF, Ogunnaike EA, Pitz M, Elbaz NM, Panda DK, Alexander-Bryant A, Saha S, Whitehead DC, Kabanov A. Enhancing drug delivery with supramolecular amphiphilic macrocycle nanoparticles: selective targeting of CDK4/6 inhibitor palbociclib to melanoma. Biomaterials Science. 2024 Jan 30;12(3):725-737.11.
2022
17 / Alatise, KL, Gardner, S, Alexander-Bryant, A. Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets. Cancers (Basel). 2022 Dec 18;14(24):6246.
16 / Samec T, Alatise KL, Boulos J, Gilmore S, Hazelton A, Coffin C, Alexander-Bryant A. Fusogenic peptide delivery of bioactive siRNAs targeting CSNK2A1 for treatment of ovarian cancer. Mol Ther Nucleic Acids. 2022 Sep 19;30:95-111.
15 / SIqbal, S, Alexander-Bryant, A, Larsen, J, 2022. Polymer-Mediated Delivery of CRISPR-Cas9 Genome Editing Therapeutics for CNS Disease. In: E. Nance (Ed.). Engineering Biomaterials for Neural Applications. Springer, Cham.
14 / Pitz M, Elpers M, Nukovic A, Wilde S, Gregory AJ, Alexander-Bryant A. De Novo Self-Assembling Peptides Mediate the Conversion of Temozolomide and Delivery of a Model Drug into Glioblastoma Multiforme Cells. Biomedicines. 2022 Sep 2;10(9):2164.
13 / Samec T, Boulos J, Gilmore S, Hazelton A, Alexander-Bryant A. Peptide-based delivery of therapeutics in cancer treatment. Mater Today Bio. 2022 Mar 30;14:100248.
12 / Pitz ME, Nukovic AM, Elpers MA, Alexander-Bryant AA. Factors Affecting Secondary and Supramolecular Structures of Self-Assembling Peptide Nanocarriers. Macromol Biosci. 2022 Feb;22(2):e2100347.
2021
11 / Attia, M, Montaser A.S., Arifuzzaman, M, Pitz, M, Jlassi, K, Alexander-Bryant, A, Kelly, S.S., Alexis, F, Whitehead, D.C., 2021. In situ Photopolymerization of Acrylamide Hydrogel to Coat Cellulose Acetate Nanofibers for Drug Delivery System. Polymers 2021, 13(11), 1863.
10 / Miller EM, Samec TM, Alexander-Bryant AA. Nanoparticle delivery systems to combat drug resistance in ovarian cancer. Nanomedicine. 2021 Jan;31:102309.
2020
9 / Mbiki, S., McClendon, J., Alexander-Bryant, A., & Gilmore, J. (2020). Classifying changes in LN-18 glial cell morphology: a supervised machine learning approach to analyzing cell microscopy data via FIJI and WEKA. Medical & biological engineering & computing, 58(7), 1419–1430.
8 / Iqbal, S., Blenner, M., Alexander-Bryant, A., & Larsen, J. (2020). Polymersomes for Therapeutic Delivery of Protein and Nucleic Acid Macromolecules: From Design to Therapeutic Applications. Biomacromolecules, 21(4), 1327–1350.
2019
7 / Caffery, B., Lee, J. S., & Alexander-Bryant, A. A. (2019). Vectors for Glioblastoma Gene Therapy: Viral & Non-Viral Delivery Strategies. Nanomaterials (Basel, Switzerland), 9(1), 105.
2017
6 / Alexander-Bryant, A, Zhang, H, Attaway, C, Pugh, W, Eggart, L, Sansevere, R, Andino, L, Dinh, Lu, Cantini, L, Jakymiw, A, 2017. Dual peptide-mediated targeted delivery of bioactive siRNAs to oral cancer cells in vivo. Oral Oncology, 72: 123-131.
5 / Alexander-Bryant, A, Hourigan, B, Lynn, M, Lee, JS, “Nanotherapeutics for combination drug and gene therapy in treating glioblastoma multiforme,” Proceedings: AACR 108th Annual Meeting 2017, American Association for Cancer Research, Washington, DC (April 2017).
2016
4 / Alexander-Bryant, A, Zhang, H, Pugh, W, Dinh, Lu, Attaway, C, Laurence, E, Sansevere, R, Jakymiw, A. “Dual peptide-mediated targeted delivery of siRNAs for the treatment of oral cancer,” Proceedings: AACR 107th Annual Meeting 2016, American Association for Cancer Research, New Orleans, LA (April 2016).
2015
3 / Alexander-Bryant, A, Dumitriu, A, Attaway, C, Yu, H, Jakymiw, A, 2015. Fusogenic-oligoarginine peptide-mediated silencing of the CIP2A oncogene suppresses oral cancer tumor growth in vivo. Journal of Controlled Release, 218: 72-81.
2 / Alexander-Bryant, A, Dumitriu, A, Attaway, C, Yu, H, Jakymiw, A. “Fusogenic-oligoarginine peptide-mediated silencing of the CIP2A oncogene suppresses oral cancer tumor growth in vivo,” Proceedings: AACR 106th Annual Meeting 2015, American Association for Cancer Research, Philadelphia, PA (April 2015).
2013
1 / Alexander-Bryant, A.A., Vanden Berg-Foels, W.S., Wen, X, 2013. Bioengineering strategies for designing targeted cancer therapies. Advances in Cancer Research 118, 1-59.